NanoString Technologies
NSTGNanoString Technologies, Inc. (NASDAQ: NSTG) is a United States-based company that provides life science tools for translational research and molecular diagnostics. Its primary business focus is the development and commercialization of two core technology platforms. The nCounter Analysis System is a tool for profiling up to 800 targets in a single reaction without amplification, used for gene expression, copy number variation, and protein analysis. The GeoMx Digital Spatial Profiler is a platform designed for spatial biology, enabling researchers to characterize proteins and RNA in tissue samples while preserving spatial context. The company's platforms are utilized by researchers in academic, government, and biopharmaceutical institutions. Their tools are applied in key therapeutic areas including oncology, immunology, and neuroscience. The data generated from NanoString's systems is intended to aid in the discovery and development of potential biomarkers and therapeutic targets, supporting the field of translational research that bridges basic science and clinical application. NanoString Technologies operates globally, with its tools employed in various research applications. The company's product portfolio includes its instrumentation systems, associated consumables, and software for data analysis. As a publicly traded entity, its financial performance and corporate developments are documented through its SEC filings and public announcements.
About
NanoString Technologies, Inc. (NASDAQ: NSTG) is a United States-based company that provides life science tools for translational research and molecular diagnostics. Its primary business focus is the development and commercialization of two core technology platforms. The nCounter Analysis System is a tool for profiling up to 800 targets in a single reaction without amplification, used for gene expression, copy number variation, and protein analysis. The GeoMx Digital Spatial Profiler is a platform designed for spatial biology, enabling researchers to characterize proteins and RNA in tissue samples while preserving spatial context. The company's platforms are utilized by researchers in academic, government, and biopharmaceutical institutions. Their tools are applied in key therapeutic areas including oncology, immunology, and neuroscience. The data generated from NanoString's systems is intended to aid in the discovery and development of potential biomarkers and therapeutic targets, supporting the field of translational research that bridges basic science and clinical application. NanoString Technologies operates globally, with its tools employed in various research applications. The company's product portfolio includes its instrumentation systems, associated consumables, and software for data analysis. As a publicly traded entity, its financial performance and corporate developments are documented through its SEC filings and public announcements.